No Data
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 3.7%
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) was down 3.7% on Monday . The company traded as low as $15.16 and last traded at $15.16. Approximately 16,314 shares changed hands during mid-day
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
Aclaris Therapeutics (NASDAQ:ACRS) Trading 5.5% Higher
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) shares traded up 5.5% during mid-day trading on Monday . The stock traded as high as $13.85 and last traded at $13.79. 3,630 shares changed hands
Global Alopecia Treatment Market Report 2022: Industry Size, Share Growth and Forecast 2027
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Drops By 10.0%
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) was the recipient of a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 3,140,000 share
Cantor Fitzgerald Biotech/pharma Analysts Hold Analyst/industry Conference Call
Great Point Partners LLC Boosts Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Great Point Partners LLC boosted its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) by 17.8% during the 1st quarter, according to its most recent 13F filing with the Securities an
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Parkman Healthcare Partners LLC
Parkman Healthcare Partners LLC trimmed its holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) by 34.9% in the first quarter, Holdings Channel reports. The fund owned 668,098 shares o
Integral Health Asset Management LLC Has $4.10 Million Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Integral Health Asset Management LLC lifted its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) by 19.0% during the 1st quarter, according to its most recent filing with
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, CEO o
Loading...
